Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tegoprazan plus amoxicillin versus esomeprazole-based bismuth quadruple therapy for Helicobacter pylori eradication
ChiCTR2200067051Phase 4Recruiting
- Sponsor
- Eighth Affiliated Hospital of Sun Yat-sen University
- Start
- Dec 2022
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tegoprazan, amoxicillin, esomeprazole, clarithromycin and bismuth subcitrate in Helicobacter pylori infection (2 arms), sponsored by Eighth Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Helicobacter pylori eradication rate. Started Dec 2022; status: recruiting.
02
Drugs
tegoprazanamoxicillinesomeprazoleclarithromycinbismuth subcitrate
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2200067051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200067051.